{"organizations": [], "uuid": "2c5311a6de6289cf477df338ef836f2edcbb51e6", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180405.html", "section_title": "Archive News &amp; Video for Thursday, 05 Apr 2018 | Reuters.com", "url": "https://www.reuters.com/article/health-sarepta/sarepta-therapeutics-beats-bid-to-revive-shareholder-class-action-idUSL2N1RI29Z", "country": "US", "domain_rank": 408, "title": "Sarepta Therapeutics beats bid to revive shareholder class action", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-04-06T07:30:00.000+03:00", "replies_count": 0, "uuid": "2c5311a6de6289cf477df338ef836f2edcbb51e6"}, "author": "Nate Raymond", "url": "https://www.reuters.com/article/health-sarepta/sarepta-therapeutics-beats-bid-to-revive-shareholder-class-action-idUSL2N1RI29Z", "ord_in_thread": 0, "title": "Sarepta Therapeutics beats bid to revive shareholder class action", "locations": [], "entities": {"persons": [], "locations": [{"name": "cambridge", "sentiment": "none"}, {"name": "boston", "sentiment": "none"}], "organizations": [{"name": "sarepta therapeutics inc", "sentiment": "negative"}, {"name": "sarepta therapeutics", "sentiment": "negative"}, {"name": "fda", "sentiment": "none"}, {"name": "u.s. food and drug administration", "sentiment": "none"}, {"name": "1st u.s. circuit court of appeals", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "A federal appeals court has upheld the dismissal of a lawsuit accusing Sarepta Therapeutics Inc of misleading shareholders by suggesting it had gathered enough data to seek U.S. Food and Drug Administration approval in 2014 to market a treatment for a rare muscle disorder.\nThe 1st U.S. Circuit Court of Appeals in Boston on Wednesday ruled in favor of the Cambridge, Massachusetts-based drugmaker, finding that a statement the FDA issued related to the approval process did not render the companyâ€™s own statements misleading.\nTo read the full story on WestlawNext Practitioner Insights, click here: bit.ly/2JpuvLF\n ", "external_links": ["https://twitter.com/reuters", "https://www.youtube.com/user/ReutersVideo", "http://thomsonreuters.com/en/about-us/trust-principles.html", "https://www.linkedin.com/company/10256858/", "https://www.facebook.com/Reuters", "https://www.thomsonreuters.com/en/privacy-statement.html", "http://bit.ly/2JpuvLF", "https://instagram.com/reuters/"], "published": "2018-04-06T07:30:00.000+03:00", "crawled": "2018-04-06T21:59:55.009+03:00", "highlightTitle": ""}